Emendo Biotherapeutics

DNA Correction and Genome-editing Platforms

Health Tech & Life Sciences
Acquired by AnGes on Dec, 2020

Company Overview

Snapshot

Founded in May 2015 by Lior Izhar, Emendo Biotherapeutics operates with 11–50 employees. The company raised $73M across two funding rounds before being acquired by AnGes in December 2020.

Business overview

Emendo Biotherapeutics specializes in developing next-generation gene-editing tools designed to address genetic disorders. The company's core technology focuses on recombination-based genome-editing solutions that aim to repair and eliminate genetic mutations in living cells with high specificity and zero off-target effects. Emendo serves the health tech and life sciences sector, specifically targeting the pharmaceutical and biotechnology industries with its gene therapy advancements.

Strategic signal

In December 2023, AnGes initiated layoffs impacting 110 EmendoBio employees, three years after its $250 million acquisition of the company. This development signals a significant restructuring within the acquired entity, indicating potential shifts in strategic focus or operational integration challenges post-acquisition for investors monitoring the long-term viability of M&A in the gene-editing space.

Company Intelligence Q&A

What is Emendo Biotherapeutics' primary focus?
Emendo Biotherapeutics develops next-generation gene-editing tools for genetic disorders, focusing on repairing and eliminating genetic mutations in living cells.
When was Emendo Biotherapeutics acquired?
Emendo Biotherapeutics was acquired by AnGes in December 2020.
What was a key development for Emendo Biotherapeutics in May 2022?
In May 2022, Emendo Biotherapeutics presented breakthrough results for its allele-specific CRISPR gene-editing technologies in treating ELANE-related Severe Congenital Neutropenia at the ASGCT Annual Meeting.
Which investors participated in Emendo Biotherapeutics' January 2020 funding round?
In January 2020, Emendo Biotherapeutics raised capital from OrbiMed and Takeda Ventures.
What significant operational change occurred at EmendoBio in December 2023?
In December 2023, AnGes initiated layoffs affecting 110 EmendoBio employees, three years after acquiring the company.

External links